Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLópez Sánchez, Cristina
dc.contributor.authorValcarcel Ferreiras, David
dc.contributor.authorGómez, Valle
dc.contributor.authorLópez-Jiménez, Javier
dc.contributor.authorSerrano, David
dc.contributor.authorRubio, Vicente
dc.contributor.authorRuiz Camps, Isabel
dc.date.accessioned2021-10-27T12:46:31Z
dc.date.available2021-10-27T12:46:31Z
dc.date.issued2020-04
dc.identifier.citationLópez-Sánchez C, Valcárcel D, Gómez V, López-Jiménez J, Serrano D, Rubio V, et al. Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC). Rev Española Quimioter. 2020 Apr;33(2):110–5.
dc.identifier.issn0214-3429
dc.identifier.urihttp://hdl.handle.net/11351/6473
dc.descriptionStem cell transplantation; Micafungin; Prophylaxis
dc.description.abstractIntroduction. The fungal infections remain an important problem in the allogeneic stem cell trasnsplantation (allo-SCT) setting and thus, anti-fungal prophylaxis is commonly used. The antifungal drug should offer activity, at least against Candida and Aspergillus spp., a good safety profile and low probability interactions. Micafungin could theoretically fulfill these requisites. The aim of the study was to describe the experience with micafungin as primary prophylaxis in patients undergoing allo-SCT in a cohort of Spanish centres, and to evaluate its ef-ficacy and tolerability in this population. Material and methods. Retrospective multicentre observational study including all consecutive adult patients admitted for allo-SCT in participating centres of the Grupo Español de Trasplante Hematopoyético (GETH), from January 2010 to December 2013, who received micafungin as primary prophylaxis during the neutropenic period. Results. A total of 240 patients from 13 centres were identified and 159 patients were included for the analysis. Most patients (95.6%) received 50 mg/day of micafungin. During the follow-up, 7 (4.4%) patients developed breakthrough invasive fungal disease, 1 proven and 6 probable; one patient discontinued the drug because of serious drug interactions. Prophylaxis with micafungin was considered effective in 151 (94.9%) patients. Conclusions. According to our experience, micafungin is an appropriate alternative for antifungal prophylaxis in patients undergoing an allo-HSCT, because its efficacy, its low profile of drug interactions and side-effects.
dc.language.isoeng
dc.publisherSociedad Española de Quimioterapia
dc.relation.ispartofseriesRevista Española de Quimioterapia;33(2)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectMicosi - Prevenció
dc.subjectCèl·lules mare hematopoètiques - Trasplantació
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshMycoses
dc.subject.mesh/prevention & control
dc.titleUse of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
dc.title.alternativeProfilaxis antifúngica con micafungina en pacientes que reciben un trasplante alogénico de progenitores hematopoyéticos (alo-TPH) en España (GETH-MIC)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.37201/req/094.2019
dc.subject.decstrasplante de células madre hematopoyéticas
dc.subject.decsmicosis
dc.subject.decs/prevención & control
dc.relation.publishversionhttp://www.doi.org/10.37201/req/094.2019
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[López-Sánchez C, Valcárcel D, Ruiz I] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gómez V] Hospital Universitario de La Princesa, Madrid, Spain. [López-Jiménez J] Hospital Universitario Ramón y Cajal, Madrid, Spain. [Serrano D] Hospital Universitario Gregorio Marañón, Madrid, Spain. [Rubio V] Hospital Jerez de la Frontera, Cádiz, Spain
dc.identifier.pmid32056418
dc.identifier.wos000598068100004
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record